Herriot Tabuteau, Axsome CEO (Owen Hoffmann/Patrick McMullan via Getty Images)
August 9, 2021 09:25 AM EDT
R&D
Pharma
FDA+

Let­ter from FDA out­lin­ing de­fi­cien­cies for lead drug caus­es Ax­some stock to crater. Is a CRL on the way?

Zachary Brennan

Senior Editor

The FDA has con­cerns with Ax­some’s lead and po­ten­tial block­buster drug to treat ma­jor de­pres­sive dis­or­der, which sent the com­pa­ny’s stock price down by more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times